Tune in and learn about the $660 million public offering Madrigal Pharmaceuticals received to deliver novel therapeutics for nonalcoholic steatohepatitis (NASH). Hear from Bill Sibold as he shares his experience leading one of the year's most significant biotech fundraisings, the preparations and strategies behind the raise and how this milestone positions Madrigal to bring innovative treatments to patients.
All content for Being a Life Sciences Leader is the property of Life Sciences Pennsylvania and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
Tune in and learn about the $660 million public offering Madrigal Pharmaceuticals received to deliver novel therapeutics for nonalcoholic steatohepatitis (NASH). Hear from Bill Sibold as he shares his experience leading one of the year's most significant biotech fundraisings, the preparations and strategies behind the raise and how this milestone positions Madrigal to bring innovative treatments to patients.
Suzanna Masartis, Community Liver Alliance, LIVE from LSPA's Patient Summit
Being a Life Sciences Leader
24 minutes
10 months ago
Suzanna Masartis, Community Liver Alliance, LIVE from LSPA's Patient Summit
The season finale of Being a Life Sciences Leader features a LIVE recording from our Patient Summit held in November 2024. Suzanna Masartis, CEO of the Community Liver Alliance, joins Chris and Allison Nicklin of Goodwin to discuss her journey from volunteering at a young age to advocacy and collaboration with other non-profit leaders to enact change. Hear best practices on working with your local and state legislators to educate them on legislation that affects patient access.
Being a Life Sciences Leader
Tune in and learn about the $660 million public offering Madrigal Pharmaceuticals received to deliver novel therapeutics for nonalcoholic steatohepatitis (NASH). Hear from Bill Sibold as he shares his experience leading one of the year's most significant biotech fundraisings, the preparations and strategies behind the raise and how this milestone positions Madrigal to bring innovative treatments to patients.
